In a world of evolving world of viruses and research on vaccines produced to combat them, science has struck another breakthrough.
The IAVI (International AIDS Vaccine Initiative) and Moderna recently launched the trial of an HIV Vaccine Antigens delivered through mRNA technology. The mRNA technology teaches cells how to fight a virus in the body. This is a vaccine that gives HIV-specific antigens with the purpose of inducing an immune response. “We are tremendously excited to be advancing this new direction in HIV vaccine design with Moderna’s mRNA platform,” rejoiced president and CEO of IAVI, Mark Feinberg, in a press release.
The first doses have been administered to volunteers in a clinical trial at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C. In phase 1 of the trial, researchers are convinced enough of its safety and possibility. As per The NIAID (National Institute of Allergy and Infectious Diseases), Maryland USA, HIV was identified as the cause of AIDS in the year 1985. Vaccine research for and trials for HIV have been conducted since then on.
In an interview with NBC, Dr. Fauci (American physician-scientist and Director of the National Institute of Allergy and Infectious Diseases) discussed the details regarding the HIV vaccine. He said, “Working on an HIV vaccine was extremely helpful for us to get a vaccine for sars-covid-2.” “The platform technology for vaccines, the mRNA particularly, proved to be beyond our expectations successful (in getting a vaccine for sars-covid-2). We are going to start using that technology in HIV, so one is helping the other back and forth,” he continued.
Latest Fro TF Daily Feed:
Feature Image Via Freepik.